ALLERGY THERAPEUTICS PLC

Regulatory Filings • Jul 8, 2021

National Storage Mechanism | Additional information

RNS Number : 5270E

Allergy Therapeutics PLC

08 July 2021

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics to present key scientific findings from across its research portfolio at the Congress of the European Academy of Allergy and Clinical Immunology (EAACI) 2021

08 July 2021 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces that the Group will be sharing key scientific findings from across its research portfolio at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, taking place from 10-12 July 2021.

The EAACI Congress is the world's largest scientific conference specialising in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology, an association of more than 12,000 clinicians, researchers, and allied health professionals, dedicated to improving the health of people affected by allergic diseases.

Among its 17 posters being presented, Allergy Therapeutics will share findings from:

·      a preclinical study evaluating the plant-based cucumber mosaic virus-like-particle (CuMV) used in the Group's peanut allergy vaccine candidate, which is due to enter the clinic in 2022. This virus-like-particle (VLP) technology, genetically fused with peanut allergen, is a new strategy for peanut allergy vaccination.  

·   a retrospective cohort study, intending to reflect real world conditions, which used prescription data from patients in Germany to assess the impact of subcutaneous immunotherapy to treat grass or tree pollen allergies.

·    three approaches examining the tolerability of, and impact on allergy symptoms from, ImmunoBON, the Group's novel, protein-based oral product for the general treatment of allergies, which is based on the lower incidence of allergies shown by people who live near or on a livestock farm, the so-called "farm effect".

Allergy Therapeutics will also be hosting two symposia; The Group's Digital Company Symposium is being held on Saturday 10 July at 18:00-19:30 (CET) and will consist of three presentations covering Allergy Therapeutics' latest publication on the MATA meta-analysis, lead by Prof. Ralph Mӧsges; the current landscape of insect venom allergy presented by Prof. Thilo Jakob, and the scientific background of our newest product, ImmunoBON, presented by Prof. Erika Jensen-Jarolim. A Live Q&A will follow the symposium where the audience will be able to ask questions to the speakers.

Following Erika's presentation on ImmunoBON on Saturday evening, Franziska Roth-Walter will explain the role of iron deficiency and betalactoglobulin in atopy and how supplementing patients with these micronutrients can help to improve their quality of life in a mini hybrid symposium on Sunday 11 July at 09:00-09:30 (CET).

Manuel Llobet, CEO at Allergy Therapeutics, commented: "At Allergy Therapeutics, our mission is to transform lives by breaking new ground in immunology treatments. Our research programmes are going beyond symptom management, to focus on directly treating the cause of allergy. The research that we're delighted to be sharing with research colleagues at this year's EAACI congress demonstrates the strength of our science and our commitment to developing novel, short-course immunotherapies that can help patients to change the way they think about their allergies and better manage their conditions."

The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation is below.

Abstract Name	Presentation	Poster number
MAJOR ALLERGEN QUANTIFICATION IN A HOUSE DUST MITE ADJUVANTED THERAPEUTIC PRODUCT: ANALYTICAL DEVELOPMENTS	Sviatlana Starchenka	158
IDENTIFICATION AND QUANTIFICATION OF MAJOR HOUSE DUST MITE ALLERGEN - Der p 23 - IN DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR ALLERGEN IMMUNOTHERAPY	Petra Visic	157
IMPACT OF THE ALLERGIC DISEASE ON THE CLASSROOM PERFORMANCE AND DAILY ACTIVITIES OF CHILDREN AND ADOLESCENTS WITH ALLERGIC ASTHMA CAUSED BY HOUSE DUST MITES.	Catalina Gómez	177
IMPACT OF ALLERGIC DISEASE ON THE WORK PERFORMANCE AND DAILY ACTIVITIES OF PARENTS/CAREGIVERS OF CHILDREN AND ADOLESCENTS WITH ALLERGIC ASTHMA CAUSED BY HOUSE DUST MITE	Catalina Gómez	180
EFFECTS OF A HOUSE MITE ALLERGOID ABSORBED INTO MUCROCRYSTALLINE TYROSINE ON THE IMPACT OF ASTHMA DUE TO MITE ALLERGY ON SCHOOL PERFORMANCE AND DAILY ACTIVITIES OF CHILDREN AND ADOLESCENT	Catalina Gómez	182
EFFECTIVENESS AND SAFETY OF A SUBCUTANEOUS ALLERGEN IMMUNOTHERAPY WITH A MICROCRYSTALLINE TYROSINE-ADSORBED NATIVE EXTRACT IN PATIENTS SENSITISED TO QUERCUS SPP	Immaculada Pérez-Rangel	183
STRONG REDUCTION IN NASAL PROVOCATION TEST OUTCOME AFTER TREATMENT WITH A MODIFIED BIRCH SCIT PRODUCT COMPARED TO PLACEBO: A RETROSPECTIVE SUB-STUDY OF A PIVOTAL PHASE III STUDY WITH PQ BIRCH	Pieter-Jan de Kam	234
SAFETY AND IMMUNOLOGY RESULTS FROM A PIVOTAL PHASE III STUDY WITH A MODIFIED BIRCH SCIT PRODUCT	Pieter-Jan de Kam	214
BASELINE SCORE DURING CONJUNCTIVAL PROVOCATION TESTING IS AN IMPORTANT PREDICTOR OF TREATMENT EFFECT - POST-HOC ANALYSES OF A PHASE II STUDY WITH A MODIFIED GRASS SCIT PRODUCT.	Pieter-Jan de Kam	192
SHORT-COURSE SPECIFIC IMMUNOTHERAPY (SIT) WITH MODIFIED GRASS/TREE ALLERGOID USING A MICROCRYSTALLINE TYROSINE (MCT) & MONOPHOSPHORYL LIPID A (MPL) ADJUVANT SYSTEM DECREASES BIRCH Ig E LEVELS	Dietrich Stollewerk	213
A THREE-SIDED APPROACH TO EVALUATE BOVINE BETA-LACTOGLOBULIN IN A LOZENGE - TARGETED MICRONUTRITION IN PATIENTS WITH ALLERGIC RHINOCONJUNCTIVITIS	Karl-Christian Bergmann	195
TAPAS - A LONG-TERM NON-INTERVENTIONAL STUDY USING MCT (MICROCRYSTALLINE TYROSINE) ADSORBED ALLERGOIDS TO DEMONSTRATE NON-INFERIORITY OF CHILDREN COMPARED TO ADULTS	Ralph Mӧsges	197
DESIGN, SAFETY AND EFFICACY PROFILE OF THE CUCUMBER MOSAIC VIRUS-LIKE PARTICLE (CuMV) MODIFIED BY GENETIC FUSION WITH Fel d1 FOR CAT ALLERGY TREATMENT	Thalia L. Carreño	159
DESIGN, SAFETY AND EFFICACY PROFILE OF THE CUCUMBER MOSAIC VIRUS-LIKE PARTICLE (CuMV) MODIFIED BY GENETIC FUSION WITH Ara h2 FOR PEANUT ALLERGY TREATMENT	Thalia L. Carreño	160
THE HEALTH AND ECONOMIC IMPACT OF ALLERGEN THERAPY IN PATIENTS WITH ALLERGIC RHINOCONJUNCTIVITIS: REAL-WORD EVIDENCE FROM THE CZECH REPUBLIC	Tomáš Doležal	981
EFFECTIVENESS AND SAFETY OF A MICROCRYSTALLINE TYROSINE-ADSORBED CUPRESSUS ARIZONICA ALLERGOID IN PATIENTS WITH ALLERGIC RHINITIS WITH AND WITHOUT ASTHMA: RESULTS FROM A RESTROSPECTIVE STUDY	Rosa María Blanco	1011
TARGET - IMPACT OF AUTHORIZED MICROCRYSTALLINE TYROSINE (MCT) - ADSORBED POLLEN SCIT ALLERGOIDS ON ALLERGIC RHINITIS (AR) UNDER REAL LIFE CONDITIONS	Christian Vogelberg	994

Pioneering a new age - fighting allergic disease on all fronts! Saturday 10 July 2021 18:00 - 19:30 (CET)
Introduction Chair: Dr. Ignacio Dávila	3D Adjuvants Mode of Action Video Symposium Overview& Introductions	5 mins
Speaker Prof. Ralph Mösges	MCT- an evidence-based adjuvant in allergen immunotherapy	25 mins
Speaker: Prof. Thilo Jakob	Insect Venom Allergy - exploring the current landscape	25 mins
Speaker: Prof. Erika Jensen-Jarolim	Beta-lactoglobulin - from farm stable dust to a lozenge inducing immune resilience in allergic diseases	25 mins
Chair: Dr. Ignacio Dávila	Q&A	10 mins
Allergy Therapeutics Mini Symposium Sunday 11 July 2021 09:00 - 09:30 (CET)
Franziska Roth-Walter	Ameliorating atopy by targeted micronutrient supplementation with beta-lactoglobulin	30 mins

Abstracts and links to the posters are expected to be made available on the Company's website from 12 July 2021.

No new material price sensitive information is expected to be disclosed on Allergy Therapeutics at the EAACI Congress. 

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Carina Jurs

allergytherapeutics@consilium-comms.com

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGZGGNVNRGMZM